Is rimonabant a safe and effective treatment for obesity? Commentary

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 5, 2007, Pages 388-389

  Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

BLOOD PRESSURE MEASUREMENT; BODY MASS; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; MEDLINE; META ANALYSIS; NOTE; OBESITY; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 34247547424     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0478     Document Type: Note

References (5)

1. Xu H et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830
2. Pagotto U et al. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100
3. Engeli S et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843
4. Bluher M et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053-3060
5. Nainggolan L (online 6 December 2006) SERENADE confirms efficacy of rimonabant in diabetes [http://www.medscape.com/viewarticle/548932] (Accessed 15 February 2007)